Clinical features of adults with seven-valent-conjugated-vaccine-serotype pneumococcal pneumonia

Vaccine

Volumn 32, Issue 13, 2014, Pages 1460-1465

  Rodrigo, Chamira ^a   Bewick, Thomas ^a   Sheppard, Carmen ^b   Greenwood, Sonia ^a   Trotter, Caroline ^c   Slack, Mary ^b   George, Robert ^b   Lim, Wei Shen ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Pneumococcal; Pneumonia; Serotype; Vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE; SEVEN VALENT CONJUGATED PNEUMOCOCCAL VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOASSAY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLEX IMMUNOASSAY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROTYPE; STREPTOCOCCUS PNEUMONIA; VERY ELDERLY; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

PNEUMOCOCCAL; PNEUMONIA; SEROTYPE; VACCINE;

AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; DEMENTIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDIES; RISK FACTORS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; STROKE;

EID: 84896698269     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.035     Document Type: Article

References (48)

1. Cillo'niz C., Ewig S., Polverino E., Marcos M.A., Esquinas C., Gabarru' A., et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011, 66:340-346. Published online 28 January 2011. 10.1136/thx.2010.143982.
2. Johansson N., Kalin M., Tiveljung-Lindell A., Giske C.G., Hedlund J. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010, 50(2):202-209. Published online 2009/12/18. 10.1086/648678.
3. Huang S.S., Johnson K.M., Ray G.T., Wroe P., Lieu T.A., Moore M.R., et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 2011, 29(18):3398-3412. http://dx.doi.org/10.1016/j.vaccine.2011.02.088.
4. Melegaro A., Edmunds W.J., Pebody R., Miller E., George R. The current burden of pneumococcal disease in England and Wales. J Infect 2006, 52(1):37-48. Published online 2005/12/22. 10.1016/j.jinf.2005.02.008.
5. Yu V.L., Chiou C.C.C., Feldman C., Ortqvist A., Rello J., Morris A.J., et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003, 37(2):230-237. 10.1086/377534.
6. Ewig S., Birkner N., Strauss R., Schaefer E., Pauletzki J., Bischoff H., New perspectives on community-acquired pneumonia in 388 406 patients.Results from a nationwide mandatory performance measurement programme in healthcare quality, et al. Thorax 2009, 64:1062-1069. 10.1136/thx.2008.109785.
7. Trotter C.L., Stuart J.M., George R., Miller E. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis 2008, 14(5):727-733.
8. Centers for Disease Control and Prevention. Prevention of Pneumococcal Disease: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recommendations and Reports 1997; 4(46(RR-8)):1-24. Published online.
9. Wroe P.C., Finkelstein J.A., Ray G.T., Linder J.A., Johnson K.M., Rifas-Shiman S., et al. Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis 2012, 205(10):1589-1592. 10.1093/infdis/jis240.
10. Miller E., Andrews N.J., Waight P.A., Slack M.P.E., George R.C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11(10):760-768.
11. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368(9546):1495-1502.
12. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(1):32-41.
13. Griffin M.R., Zhu Y., Moore M.R., Whitney C.G., Grijalva C.G. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013, 369(2):155-163. 10.1056/NEJMoa1209165.
14. Liesenborghs L., Verhaegen J., Peetermans W.E., Vandeven J., Flamaing J. Trends in serotype prevalence in invasive pneumococcal disease before and after infant pneumococcal vaccination in Belgium, 2002-2010. Vaccine 2013, 31(11):1529-1534. http://dx.doi.org/10.1016/j.vaccine.2012.11.103.
15. Ladhani S.N., Slack M.P., Andrews N.J., Waight P.A., Borrow R., Miller E. Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales. Emerg Infect Dis 2013, 19(1):61-68. Published online 2012/12/25. 10.3201/eid1901.120741.
16. Alanee S.R.J., McGee L., Jackson D., Chiou C.C., Feldman C., Morris A.J., et al. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis 2007, 45(1):46-51. 10.1086/518538.
17. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5(6):649-655. Published online 1982/12/01.
18. Sheppard C.L., Harrison T.G., Smith M.D., George R.C. Development of a sensitive, multiplexed immunoassay using xMAP beads for detection of serotype-specific Streptococcus pneumoniae antigen in urine samples. J. Med. Microbiol 2011, 60(1):49-55. 10.1099/jmm.0. 023150-0.
19. Luján M., Gallego M., Belmonte Y., Fontanals D., Vallès J., Lisboa T., et al. Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia. Eur Respir J 2010, 36(5):1073-1079. 10.1183/09031936.00176309.
20. Fine M.J., Auble T.E., Yealy D.M., Hanusa B.H., Weissfeld L.A., Singer D.E., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336(4):243-250. 10.1056/NEJM199701233360402.
21. Lamb K.E., Flasche S., Diggle M., Inverarity D., Greenhalgh D., Jefferies J.M., et al. Trends in serotypes and sequence types among cases of invasive pneumococcal disease in Scotland, 1999-2010. Vaccine 2013, (0). http://dx.doi.org/10.1016/j.vaccine.2013.05.079.
22. Ardanuy C., Tubau F., Pallares R., Calatayud L., Domínguez M.A., Rolo D., et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis 2009, 48(1):57-64. 10.1086/594125.
23. Burgos J., Falcó V., Borrego A., Sordé R., Larrosa M.N., Martinez X., et al. Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia. Clin Microbiol Infect 2013, 19(4):385-391. 10.1111/j. 1469-0691.2012.03895.x.
24. Steptoe A., Shankar A., Demakakos P., Wardle J. Social isolation, loneliness, and all-cause mortality in older men and women. PNAS 2013, 110(15):5797-5801. 10.1073/pnas.1219686110.
25. Hinojosa R., Haun J., Hinojosa M.S., Rittman M. Social isolation poststroke: relationship between race/ethnicity, depression, and functional independence. Top Stroke Rehabil 2011, 18(1):79-86. Published online 2011/03/05. 10.1310/tsr1801-79.
26. Nicholson N.R. A review of social isolation: an important but underassessed condition in older adults. J Primary Prev 2012, 33(2-3):137-152. Published online 2012/07/07. 10.1007/s10935-012-0271-2.
27. Kane M., Cook L. Dementia 2013: the hidden voice of loneliness 2013, 1-78.
28. Fuller-Thomson E., Minkler M. American grandparents providing extensive child care to their grandchildren: prevalence and profile. Gerontologist 2001, 41(2):201-219. 10.1093/geront/41.2.201.
29. Rodrigo C., Bewick T., Sheppard C., Greenwood S., MacGregor V., Trotter C., et al. Pneumococcal serotypes in adult non-invasive and invasive pneumonia in relation to child contact and child vaccination status. Thorax 2013, 10.1136/thoraxjnl-2013-203987.
30. Sjöström K., Spindler C., Ortqvist A., Kalin M., Sandgren A., Kühlmann-Berenzon S., et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 2006, 42(4):451-459. 10.1086/499242.
31. Bewick T., Sheppard C., Greenwood S., Slack M., Trotter C., George R., et al. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax 2012, 67(6):540-545.
32. Obaro S., Adegbola R. The pneumococcus: carriage, disease and conjugate vaccines. J Med Microbiol 2002, 51(2):98-104.
33. Horner J., Alberts M.J., Dawson D.V., Cook G.M. Swallowing in Alzheimer's disease. Alzheimer Dis Assoc Disord 1994, 8(3):177-189. Published online 1994/01/01.
34. Mann G., Hankey G.J., Cameron D. Swallowing function after stroke: prognosis and prognostic factors at 6 months. Stroke 1999, 30(4):744-748. 10.1161/01.str.30.4.744.
35. Ding R., Logemann J.A. Pneumonia in stroke patients: a retrospective study. Dysphagia 2000, 15(2):51-57. Published online 2000/04/12.
36. Prass K., Braun J.S., Dirnagl U., Meisel C., Meisel A. Stroke propagates bacterial aspiration to pneumonia in a model of cerebral ischemia. Stroke 2006, 37(10):2607-2612. 10.1161/01.STR.0000240409.68739.2b.
37. Marrie T.J. Pneumococcal pneumonia: epidemiology and clinical features. Semin Respir Infect 1999, 14(3):227-236. Published online 1999/09/29.
38. Vinogradova Y., Hippisley-Cox J., Coupland C. Identification of new risk factors for pneumonia: population-based case-control study. Br J Gen Pract 2009, 59(567):e329-e338.
39. Lipsky B.A., Boyko E.J., Inui T.S., Koepsell T.D. Risk factors for acquiring pneumococcal infections. Arch Intern Med 1986, 146(11):2179-2185.
40. Corbo J., Friedman B., Bijur P., Gallagher E.J. Limited usefulness of initial blood cultures in community acquired pneumonia. Emerg Med J 2004, 21(4):446-448.
41. Chalasani N.P., Valdecanas M.A.L., Gopal A.K., McGowan J.J.E., Jurado R.L. Clinical utility of blood cultures in adult patients with community-acquired pneumonia without defined underlying risks. CHEST J 1995, 108(4):932-936. 10.1378/chest.108.4.932.
42. Bewick T., Sheppard C., Greenwood S., Slack M., Trotter C., George R., et al. Serotypes associated with the development of pneumococcal para-pneumonic effusion in adults. Eur Respir J 2012, Published online 2012/12/22. 10.1183/09031936.00144712.
43. Ludwig E., Bonanni P., Rohde G., Sayiner A., Torres A. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012, 21(123):57-65. 10.1183/09059180.00008911.
44. Pallares R., Liñares J., Vadillo M., Cabellos C., Manresa F., Viladrich P.F., et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995, 333(8):474-480. 10.1056/NEJM199508243330802.
45. Weinberger D.M., Harboe Z.B., Sanders E.A.M., Ndiritu M., Klugman K.P., Rückinger S., et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010, 51(6):692-699. 10.1086/655828.
46. van Hoek A.J., Andrews N., Waight P.A., George R., Miller E. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS One 2012, 7(7):e39150. 10.1371/journal.pone.0039150.
47. Pilishvili T., Zell E.R., Farley M.M., Schaffner W., Lynfield R., Nyquist A-C., et al. Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use. Pediatrics 2010, 126(1):e9-e17.
48. Iliffe S., Curry L., Kharicha K., Rait G., Wilcock J., Lowery D., et al. Developing a dementia research registry: a descriptive case study from North Thames DeNDRoN and the EVIDEM programme. BMC Med Res Methodol 2011, 11(1):1-10. 10.1186/1471-2288-11-9.